原研与仿制费鲁莫司韦的弛豫率及人体内成像性能比较
本研究通过体外模体实验和健康志愿者交叉设计,比较原研(AMAG)与仿制(Sandoz)费鲁莫司韦的弛豫-浓度依赖关系及3.0T磁共振血管成像性能。结果显示两者弛豫曲线无统计学或临床相关差异,图像质量无临床相关差异,最佳翻转角为20°-30°、最佳剂量为5 mg/kg,结论认为两者可互换用于MRA。
要点
- 原研与仿制费鲁莫司韦的弛豫-浓度曲线无统计学显著或临床相关差异。
- 健康志愿者交叉试验中两种产品图像质量无临床相关差异。
- 两种产品的最佳翻转角范围为20°-30°,最佳剂量为5 mg/kg。
核心结论
- 原研与仿制费鲁莫司韦产品可在磁共振血管成像中互换使用。
研究设计与样本
- 模体实验结合健康志愿者交叉设计;模体实验使用原研(AMAG Pharmaceuticals)与仿制(Sandoz Pharmaceuticals)费鲁莫司韦,在1.5T和3.0T下测量R1、R2、R2*并估计弛豫-浓度曲线;体内剂量累积研究纳入6名健康志愿者(38.8±11.5岁,3女3男),在3.0T临床MRI系统上行胸部MRA,累积剂量为1、3、5、7 mg/kg,每个剂量翻转角从40°至10°以-10°递增共5次屏气采集后重复40°采集。
诊断标准与关键数值
- 模体实验中两种产品弛豫-浓度曲线无统计学显著或临床相关差异。
- 体内试验中两种产品图像质量无临床相关差异。
- 两种产品的最佳翻转角范围均为20°-30°,最佳剂量均为5 mg/kg。
临床应用与阅片要点
- 原研与仿制费鲁莫司韦可在MRA中互换使用。
- 行费鲁莫司韦MRA时,翻转角20°-30°、剂量5 mg/kg为最佳参数。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Ferumoxytol is a superparamagnetic iron-oxide product that is increasingly used off-label for contrast-enhanced magnetic resonance imaging (MRI) and magnetic resonance angiography (MRA). With the recent regulatory approval of generic ferumoxytol, there may be an opportunity to reduce cost, so long as generic ferumoxytol has similar imaging performance to brand name ferumoxytol. This study aims to compare the relaxation-concentration dependence and MRI performance of brand name ferumoxytol with generic ferumoxytol through phantom and in vivo experiments. The secondary purpose was to determine the optimal flip angle and optimal weight-based dosing.
MATERIALS AND METHODS: Phantom experiments were performed using both brand name (AMAG Pharmaceuticals) and generic (Sandoz Pharmaceuticals) ferumoxytol products. Each ferumoxytol product was diluted in saline, and separately in adult bovine whole blood, at 5 iron concentrations ranging from 0.3 to 2.1 mM. Vials were placed in an MR-compatible water bath at 37°C and imaged at both 1.5 T and 3.0 T. Longitudinal and transverse relaxation rate constants (R1, R2, R2*) were measured for each ferumoxytol concentration, and relaxation-concentration curves were estimated. An in vivo dose accumulation study with flip angle optimization was also implemented using a cross-over design, in healthy volunteers. Cumulative doses of 1, 3, 5, and 7 mg/kg diluted ferumoxytol were administered prior to MRA of the chest on a 3.0 T clinical MRI system. For each incremental dose, the flip angle was varied from 40° to 10° in -10° increments over 5 breath-holds followed by a repeated 40° flip angle acquisition. Regions of interest were drawn in the aortic arch, paraspinous muscles, and a noisy area outside of the patient, free from obvious artifact. Signal-to-noise ratio (SNR) was calculated as the quotient of the average signal in the aortic arch and the standard deviation of the noise, corrected for a Rician noise distribution. Contrast-to-noise ratio was calculated as the difference in SNR between the aorta and paraspinous muscles. Absolute SNR and contrast-to-noise ratio values were compared between products for different flip angles and doses.
RESULTS: There were no statistically significant or clinically relevant differences in relaxation-concentration curves between AMAG and Sandoz products in phantom experiments. Six healthy volunteers (38.8 ± 11.5 years, 3 female, 3 male) were successfully recruited and completed both imaging visits. No clinically relevant differences in image quality were observed between ferumoxytol products. The optimal flip angle range and dose for both products was 20°-30° and 5 mg/kg, respectively.
CONCLUSIONS: Brand name and generic ferumoxytol products can be used interchangeably for MRA.
引用
- van der Heijden RA, Tamada D, Mao L, et al. Relaxivity and In Vivo Human Performance of Brand Name Versus Generic Ferumoxytol. Invest Radiol. 2024. PMID: 39437023. doi:10.1097/RLI.0000000000001130
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。